Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ivermectin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Albendazole | ACTIVE_COMPARATOR | Albendazole for 7 days |
| ivermectin | EXPERIMENTAL | ivermectin 200 mcg/kg single dose |
| ivermectin 2 doses | EXPERIMENTAL | ivermectin 200 mcg/kg two doses in 2 weeks |
| Name | Type | Description |
|---|---|---|
| Ivermectin | DRUG | single dose of 200 mcg/kg |
| Albendazole | DRUG | Albendazole 7 days |
Inclusion Criteria: * Patients with positive strongyloides larva in the stool Exclusion Criteria: * Pregnancy * Lactating women * Known allergy to any study drug
Ivermectin is a small molecule being developed for the treatment of Chronic Strongyloidiasis, a parasitic infection. It is currently in Phase 3 clinical development and has been studied in a completed trial comparing it to albendazole in patients with this condition.
The specific molecular target of Ivermectin is not disclosed in the available information. It is known to be an antiparasitic agent, but the exact target for its use in Chronic Strongyloidiasis has not been specified.
Ivermectin is being developed by Atlantic International Corp., a company listed under the ticker ATLN. The company is conducting clinical trials to evaluate the drug for the treatment of Chronic Strongyloidiasis.
Ivermectin is in Phase 3 clinical development for Chronic Strongyloidiasis. A Phase 3 trial has been completed, and the drug remains investigational as it has not been approved for this indication.
Ivermectin has one completed Phase 3 trial, NCT00765024, titled 'Ivermectin Versus Albendazole for Chronic Strongyloidiasis'. This active-controlled study enrolled 90 participants in Thailand and evaluated the drug in adults aged 18 years and older.
Ivermectin is also known by the brand name Stromectol. The drug is being developed by Atlantic International Corp. for Chronic Strongyloidiasis, and the clinical trial data refers to it as Ivermectin.